- Alector, Inc (Nasdaq: ALEC) is a clinical-stage biopharmaceutical company focused on immuno-neurology, immune dysfunction studies related to degenerative brain disorders.
- Alector has 4-clinical phase therapeutics entirely targeting primarily neurological diseases including Alzheimer's and Frontotemporal Dementia. Alector also has 2-preclinical therapeutics, and 8 in the research phase.
- Alector has raised +$228M in 1Q 2020 from a stock issuance, prior to AL001's Phase 3 initiation bringing their cash basis to $462M, sufficient for approximately 4-years of cash burn.
- Alector's critical catalyst in 2021 is AL001's data readout from FTD-GRN's Phase 2 96W Study, which is expected to produce data missing from July's readout.
- In summary, the author projects Alector, Inc. (Nasdaq: ALEC) as a "buy" at a 1-year price target of $20.03 (+38% upside).
For further details see:
Alector: AL001's Phase 3 Initiation/Phase 2 Readout In 2021, $462M In Cash, And AbbVie's Promising Support, +38% Upside